Apnimed Reports Q2 2026 Results and Oxnimbi NDA Update
Health
Earnings
IPO:
Jul 31, 2026
Industry:
PHARMACEUTICAL PREPARATIONS
Show Chart?
Load external content from TradingView!
*You can change or withdraw your consent at any time in the footer under Cookies.
Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate Update
CAMBRIDGE, Mass., USA - Apnimed, Inc. (Nasdaq: APMD), a late stage clinical pharmaceutical company, reported its financial results for the second quarter ended June 30, 2026, and provided a corporate update, highlighted by the FDA acceptance of the NDA for AD109, proposed as Oxnimbi, for obstructive sleep apnea.
... Read on — Members only
About Apnimed, Inc.
We are a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases. Our sole clinical product candidate, AD109 (Oxnimbi), is an investigational, fixed-dose, anti-apneic neuromuscular modulator, combining a novel anti-muscarinic and a selective norepinephrine reuptake inhibitor (NRI) for the treatment of obstructive sleep apnea (OSA).
Health
Daily overview of upcoming SPAC and IPO events – from initial announcement to definitive agreement and public listing.
Discover last week’s SPAC and IPO highlights, key trends, and market updates. Stay informed with SpacStar.